Redeye Neurology Seminar
Gunilla Osswald, CEO, presents BioArctic and participates in a panel discussion at the Redeye Neurology Seminar in Stockholm, Sweden. BioArctic presentation (in Swedish) Panel discussion (in ...
Presentations
Alzheimer’s Association International Conference 2019 in Los Angeles
The antibody BAN2401 was designed and generated to selectively target toxic protofibrils and oligomers, soluble aggregated forms of amyloid-beta.
Interim Report January – June 2019 – Presentation
BioArctic: Significant progress in the projects and additional milestone payment
Redeye – CEO interview
Get to know BioArctic’s CEO Gunilla Osswald, an interview by Redeye’s Equity Analyst Eddie Palmgren. Video (in Swedish).
Redeye Growth Day Presentation and Interview with EFN
Gunilla Osswald, CEO, presented BioArctic at the Redeye Growth Day in Stockholm, Sweden. Video (in Swedish) EFN Interview (in Swedish) https://www.efn.se/bors-finans/biorctic-ser-framgangar-inom-samtliga-omraden/
Jefferies 2019 Global Healthcare Conference
Gunilla Osswald, CEO, presented BioArctic at Jefferies 2019 Global Healthcare Conference in New York.
Interim Report January – March 2019 – Presentation
BioArctic’s partner Eisai initiated Phase 3-study with BAN2401 in Alzheimer’s disease. Phase 1-study with ABBV-0805 in the Parkinson program started
BioStock Live panel discussion “The Alzheimer Challenge”
Watch the replay of the panel discussion on April 29th at BioStock on "The Alzheimer Challenge" with BioArctic's CEO, Gunilla Osswald.
Redeye – CEO presentation and interview
Gunilla Osswald, CEO, presented BioArctic at Redeye’s lunch meeting in Stockholm, Sweden, on April 3.
Carnegie Nordic Healthcare Seminar
Gunilla Osswald, CEO, presented BioArctic at the Carnegie Nordic Healthcare Seminar in Stockholm, Sweden.
Full Year Report January – December 2018 – Presentation
BioArctic’s partner Eisai will initiate BAN2401 confirmatory Phase 3-study in early Alzheimer’s disease. AbbVie in-licensed the Parkinson portfolio.
Redeye – CEO interview
BioArctic announced on February 4 that Eisai will initiate Phase 3 confirmatory study with BAN2401 in early Alzheimer’s Disease. Interview with CEO Gunilla Osswald here.
Aktiespararna Life Science in Stockholm
Gunilla Osswald, CEO, presented BioArctic at Aktiespararna’s Life Science evening event in Stockholm, Sweden, on January 21.
Interview with Gunilla Osswald, CEO
Gunilla Osswald, CEO, was interviewed by Klas Palin, life science analyst at Redeye, in Stockholm on December 14, 2018.
DNB’s Annual Nordic Healthcare Conference in Oslo
Gunilla Osswald, CEO, presented BioArctic at DNB’s 9th Nordic Healthcare Conference in Oslo, Norway, on December 12.
Nordea Tech & Medtech/Life Science Seminar in Stockholm
Gunilla Osswald, CEO, presented BioArctic at the Nordea Tech & Medtech/Life Science Seminar in Stockholm, Sweden, on November 27.
Stora Aktiedagen in Stockholm
Gunilla Osswald, CEO, presented BioArctic at the “Stora Aktiedagen” in Stockholm, Sweden, on November 26.
Jefferies 2018 London Healthcare Conference
Gunilla Osswald, CEO, presented BioArctic at Jefferies 2018 London Healthcare Conference.
Biotech and Money in London
Gunilla Osswald, CEO, presented BioArctic at Biotech and Money, Investival Showcase, on November 13 in London.
Interim Report January – September 2018 – Presentation
BioArctic reports strong BAN2401 Phase 2b results for Alzheimer patients. AbbVie exercises its option to a license for Parkinson’s projects.
Redeye CNS Biotech Seminar
Gunilla Osswald, PhD, CEO, presents BioArctic at Redeye CNS Biotech Seminar in Stockholm, Sweden.
Interim Report January – June 2018 – Presentation
Positive results of the BAN2401 Phase 2b study in early Alzheimer’s disease
Redeye Growth Day
Gunilla Osswald, PhD, CEO, presents BioArctic at Redeye Growth Day in Stockholm, Sweden.
Annual General Meeting 2018
Presentation at BioArctic AB's Annual General Meeting 2018.
Interim Report January – March 2018 – Presentation
Continued progress of the project portfolio.
Carnegie Healthcare Seminar 2018
Gunilla Osswald, PhD, CEO, presented BioArctic at the Carnegie Healthcare Seminar 2018 on March 14 in Stockholm, Sweden.
11th Annual European Life Sciences CEO Forum & Exhibition for Partnering & Investing in Biotech & Pharma Industry, Zurich, Switzerland
Gunilla Osswald, CEO of BioArctic AB, presented the company at the 11th Annual European Life Sciences CEO Forum & Exhibition for Partnering & Investing in Biotech ...
Full Year Report January – December 2017 – Presentation
Successful IPO and continued positive result for BioArctic
DNB Nordic Healthcare Conference
Gunilla Osswald, CEO of BioArctic AB, presented the company at DNB Nordic Healthcare Conference in Oslo, Norway, on December 14, 2017.
Carnegie Nordic Healthcare Day in New York
Gunilla Osswald, CEO of BioArctic AB, presented the company at Carnegie Nordic Healthcare Day in New York on December 5, 2017.
Evercore ISI in New York
Gunilla Osswald, PhD, CEO, and Lars Lannfelt, Professor, MD, Senior Advisor and Co-Founder presented BioArctic at Evercore ISI in New York. The lunch meeting took place ...